CN104321070A - Alk1拮抗剂及其在治疗肾细胞癌中的用途 - Google Patents

Alk1拮抗剂及其在治疗肾细胞癌中的用途 Download PDF

Info

Publication number
CN104321070A
CN104321070A CN201380013788.3A CN201380013788A CN104321070A CN 104321070 A CN104321070 A CN 104321070A CN 201380013788 A CN201380013788 A CN 201380013788A CN 104321070 A CN104321070 A CN 104321070A
Authority
CN
China
Prior art keywords
alk1
rcc
methods according
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380013788.3A
Other languages
English (en)
Chinese (zh)
Inventor
R·S·巴特
R·库马
J·W·梅尔
R·皮尔索尔
M·舍曼
N·索尔班
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Acceleron Pharma Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Acceleron Pharma Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of CN104321070A publication Critical patent/CN104321070A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201380013788.3A 2012-02-02 2013-02-01 Alk1拮抗剂及其在治疗肾细胞癌中的用途 Pending CN104321070A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261593864P 2012-02-02 2012-02-02
US61/593,864 2012-02-02
US201261597124P 2012-02-09 2012-02-09
US61/597,124 2012-02-09
PCT/US2013/024510 WO2013116781A1 (en) 2012-02-02 2013-02-01 Alk1 antagonists and their uses in treating renal cell carcinoma

Publications (1)

Publication Number Publication Date
CN104321070A true CN104321070A (zh) 2015-01-28

Family

ID=48903082

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013788.3A Pending CN104321070A (zh) 2012-02-02 2013-02-01 Alk1拮抗剂及其在治疗肾细胞癌中的用途

Country Status (11)

Country Link
US (1) US20130202594A1 (enExample)
EP (1) EP2809335A4 (enExample)
JP (1) JP2015506961A (enExample)
KR (1) KR20140123558A (enExample)
CN (1) CN104321070A (enExample)
AU (1) AU2013214779A1 (enExample)
BR (1) BR112014019151A2 (enExample)
CA (1) CA2863188A1 (enExample)
MX (1) MX2014009277A (enExample)
RU (1) RU2633638C2 (enExample)
WO (1) WO2013116781A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106994181A (zh) * 2017-03-10 2017-08-01 上海交通大学医学院附属第九人民医院 Bmp9在制备延缓肝纤维化药物中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
MX2009004718A (es) 2006-11-02 2009-06-19 Acceleron Pharma Inc Antagonistas de receptor de alk1 y ligando y sus usos.
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
CA2944335A1 (en) * 2014-03-28 2015-10-01 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
EP3268025B1 (en) * 2015-03-10 2020-05-06 University of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
EP3303387A2 (en) 2015-06-05 2018-04-11 Novartis AG Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
WO2019173482A1 (en) * 2018-03-06 2019-09-12 Sanford Burnham Prebys Medical Discovery Institute 4-aminoquinoline compounds for the treatment of angiogenesis
CN121127500A (zh) 2023-04-07 2025-12-12 达科纳治疗有限公司 针对激活素a受体样1型(alk1)的双特异性激动性抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101652387A (zh) * 2006-11-02 2010-02-17 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
CN102099374A (zh) * 2008-05-02 2011-06-15 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US6858598B1 (en) * 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20070105887A1 (en) * 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
EP2368566A1 (en) * 2006-07-13 2011-09-28 ZymoGenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CA2685306A1 (en) * 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
PE20090983A1 (es) * 2007-11-09 2009-08-13 Genentech Inc Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina
CA2720943A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
WO2011127519A1 (en) * 2010-04-15 2011-10-20 Vegenics Pty Limited Combination treatment with vegf-c antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101652387A (zh) * 2006-11-02 2010-02-17 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
CN102099374A (zh) * 2008-05-02 2011-06-15 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHO, ET AL.: "Future directions in renal cell carcinoma", 《HEMATOL ONCOL CLIN NORTH AM》, vol. 25, no. 4, 31 December 2011 (2011-12-31), pages 917 - 935, XP055159739, DOI: doi:10.1016/j.hoc.2011.05.001 *
ESCUDIER B.: "Sorafenib in advanced clear-cell renal-cell carcinoma", 《N ENGL J MED》, vol. 356, no. 2, 11 January 2007 (2007-01-11), pages 125 - 134, XP055159735 *
MOIZER: "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma", 《J CLIN ONCOL》, vol. 27, no. 22, 31 December 2009 (2009-12-31), pages 3584 - 3590, XP055159728, DOI: doi:10.1200/JCO.2008.20.1293 *
SARA I.CUNBA: "Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis", 《J EXP MED》, vol. 207, no. 1, 18 January 2010 (2010-01-18), pages 85 - 100 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106994181A (zh) * 2017-03-10 2017-08-01 上海交通大学医学院附属第九人民医院 Bmp9在制备延缓肝纤维化药物中的应用

Also Published As

Publication number Publication date
AU2013214779A1 (en) 2014-09-04
MX2014009277A (es) 2015-03-03
RU2014134923A (ru) 2016-03-27
WO2013116781A1 (en) 2013-08-08
RU2633638C2 (ru) 2017-10-16
EP2809335A1 (en) 2014-12-10
EP2809335A4 (en) 2015-10-28
JP2015506961A (ja) 2015-03-05
BR112014019151A2 (pt) 2017-06-27
US20130202594A1 (en) 2013-08-08
KR20140123558A (ko) 2014-10-22
CA2863188A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
AU2018200237B2 (en) Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
RU2559532C2 (ru) Антагонисты рецептора и лигандов alk1 и их применение
RU2633638C2 (ru) Антагонисты alk1 и их применение в лечении почечно-клеточной карциномы
US9452197B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US20220017600A1 (en) Methods and compositions for modulating angiogenesis and pericyte composition
EP2291401A2 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
HK1229690A1 (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
HK1229690A (en) Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150128